The dysregulation of PHI-1 expression—whether through gene amplification, post-transcriptional modulation, or post-translational modifications—consistently correlates with aggressive tumor phenotypes and poor clinical outcomes. This evidence concerns the gene PPP1R14B and neoplasm.